Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Celsion (CLN AMEX) was CELN -- Ignore unavailable to you. Want to Upgrade?

To: Tech Master who wrote (786)	8/4/2001 7:21:17 AM
From: telephonics	Respond to of 966

Hope you are right!

To: Tech Master who wrote (786)	8/20/2001 10:17:33 AM
From: TEDennis	Respond to of 966

Monday August 20, 9:39 am Eastern Time Press Release SOURCE: Celsion Corporation Celsion Reports Progress Towards Completion of BPH Clinical Trials COLUMBIA, Md., Aug. 20 /PRNewswire/ -- In a letter to shareholders issued today, CELSION CORPORATION (Amex: CLN - news) reported that it is moving forward towards completion of its Benign Prostatic Hyperplasia (BPH) Pivotal Phase II Clinical Trials. The Company reported that it has engaged 10 active clinical sites, collectively employing over 150 urologists treating more than 20,000 patients each month. The Company also reported a significant increase in patient enrollment during recent months. According to the letter, if the acceleration in enrollment is sustained, enrollment in the trials could be completed by the end of October 2001. In the same letter, Celsion updated its shareholders on the progress of its other businesses including the Pivotal Phase II Clinical Trials of the Company's investigational system using focused heat to treat breast cancer; the status of development of its doxorubicin-laden heat activated liposome cancer drug, currently in large animal toxicity studies; progress in the development of its heat activated gene therapy; developments arising from its relationship with Inabata: and its cash position. Celsion also advised shareholders that, in future, it expects to host quarterly shareholder conference calls, the first of which will take place on August 28, 2001 at 10:00 a.m. Eastern Daylight Savings Time. Call-in information is contained in the letter to shareholders, which is available on the Company's web site at www.celsion.com About Celsion: Celsion Corporation, based in Columbia, Maryland, is a research and development company dedicated to commercializing medical treatment systems for cancer and other diseases using focused heat technology delivered by patented microwave technology. Celsion has research, license or commercialization agreements with leading institutions such as Duke University Medical Center, Massachusetts Institute of Technology, Harbor UCLA Medical Center, the University of California at San Francisco, the Center for Breast Surgery at Columbia Hospital in Florida, Montefiore Medical Center, Memorial Sloan Kettering Cancer Center in New York and Duke University. For more information on Celsion, visit our website: http//www.celsion.com. biz.yahoo.com